



Schweizerische Pädiatrische Onkologie Gruppe
Groupe d'Oncologie Pédiatrique Suisse
Gruppo d'Oncologia Pediatrica Svizzera
Swiss Paediatric Oncology Group

CWS registry SoTiSaR

A registry for soft tissue sarcoma and other soft tissue tumours in children, adolescents and young adults

Background

This is a registry study. This means that no medicines will be tested. It only involves the collection and processing of data. This study is being carried out by the Cooperative Soft Tissue Sarcoma study group (CWS is the German abbreviation of this group's name). The study group is under the patronage of the Society of Paediatric Oncologists and Haematologists (GPOH) and works on the diagnosis and therapy of children and adolescents with soft tissue sarcomas. The Swiss Paediatric Oncology Group (SPOG) is responsible for performing the study in Switzerland. In addition to hospitals in Switzerland and Germany, hospitals in Austria, Poland and Sweden are also taking part in the study. Patients with a soft tissue sarcoma who are under 21 years of age can be enrolled in the registry study.

Why does the study need to be done?

A soft tissue sarcoma is diagnosed in only a very small number of patients (approx. 7 to 10 per year) in Switzerland. Since soft tissue sarcomas comprise more than 25 different types of cancer, it is desirable to carefully document information about all these patients who have rare cancers and to compile it in one place. This is the only way to find out about the results of therapy and the prognosis. Existing tumour samples are checked again by pathologists who specialise in soft tissue sarcomas (known as reference pathologists) to be certain that the diagnosis is correct. Centralised compilation of the data and their analysis provides information on the best way to treat soft tissue sarcomas and what affected patients can expect, e.g. what their chances of recovery are or the best way to examine them after therapy has ended in order to identify any recurrence of the disease. The main aim of this study is therefore to analyse the quality and the outcomes of treatment. In addition, the current classification of tumour types according to risk factors will be reviewed and new risk factors may be identified. The results will also create a basis for performing clinical trials in which new therapies will be tested. The compiled information will additionally be made available to researchers, doctors and patients in general.

Contact details for the sponsor representative in Switzerland:

Fundraising
SPOG Coordinating Center
Effingerstrasse 33
3008 Bern
Phone: +41 31 389 91 89